Funding for this research was provided by:
National Institutes of Health (R01 CA224917)
Center for Individualized Medicine, Mayo Clinic
Center for Biomedical Discovery, Mayo Clinic
Received: 30 June 2020
Accepted: 21 December 2020
First Online: 18 January 2021
Ethics approval and consent to participate
: This study was approved by Mayo Clinic’s Institutional Review Board. Participants were previously consented by the Mayo Clinic Nephrectomy Registry.
: THH: Advisory board participation: Surface Therapeutics, Exelixis, Genentech, Pfizer, Ipsen, Cardinal Health; research support-Novartis. The remaining authors declare no conflict of interest.